According to a recent LinkedIn post from Range, Meta’s proposed $2 billion acquisition of Manus, described as an AI startup reaching $100 million in ARR unusually quickly, is facing a forced unwind by Chinese authorities. The post notes that the deal had reportedly closed in December and that around 100 Manus employees had already relocated to Meta’s Singapore office.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post suggests that China’s state planner is now treating advanced AI as a strategic asset, comparable to how the U.S. handles semiconductors as critical technology. For investors, this interpretation points to a more restrictive environment for cross-border M&A involving AI companies with “Chinese DNA,” potentially increasing regulatory risk, prolonging deal timelines, and complicating valuations for targets with Chinese IP, founders, or investors.
As shared in the post, the situation implies that U.S. technology buyers may face heightened uncertainty when pursuing AI assets connected to China, even when operations or staff have already begun integration. This could redirect capital toward jurisdictions perceived as lower risk from a national-security standpoint and may also impact exit options and funding costs for AI startups with mixed U.S.-China exposure.
The post further indicates that any U.S. acquisition of AI firms tied to Chinese investors such as Tencent or Alibaba may encounter greater scrutiny or intervention. If this trend persists, investors might expect a bifurcation in global AI markets, with tighter controls on cross-border technology flows, potential discounts applied to deals with regulatory overhang, and increased importance of regulatory due diligence in transaction planning.